previous
cyclophilin
inhibitor
cyclosporin
csa
alisporivir
alv
shown
inhibit
replic
divers
rna
virus
includ
arterivirus
coronavirus
belong
order
nidoviral
aim
identifi
arteriviru
protein
involv
ofact
cyclophilin
inhibitor
investig
compound
inhibit
arteriviru
rna
synthesi
infect
cell
repeat
passag
arteriviru
prototyp
equin
arter
viru
eav
presenc
csa
reveal
reduc
drug
sensit
associ
emerg
adapt
mutat
nonstructur
protein
one
transmembran
subunit
arteriviru
replicas
polyprotein
introduct
singular
mutat
led
decreas
sensit
csa
treatment
wherea
combin
mutat
increas
eav
csa
resist
detail
experiment
character
engin
eav
mutant
harbor
csaresist
mutat
implic
arteriviru
rna
synthesi
particularli
vitro
assay
eav
rna
synthesi
far
less
sensit
csa
treatment
contain
adapt
mutat
mention
interestingli
increas
sensit
closelyrel
drug
alv
csaresist
mutant
requir
incorpor
addit
adapt
mutat
resid
anoth
transmembran
subunit
arteriviru
replicas
studi
provid
first
evid
involv
mechan
underli
inhibit
arteriviru
replic
cyclophilin
inhibitor
right
reserv
reus
allow
without
permiss
howev
coronavirus
seem
much
less
affect
deplet
cypa
infect
cell
de
wild
et
present
studi
aim
investig
molecular
detail
inhibit
arteriviru
replic
cyclophilin
inhibitor
end
first
passag
eav
presenc
inhibitori
csa
concentr
induc
resist
compound
subsequ
adapt
mutat
markedli
decreas
sensit
eav
replic
csa
treatment
found
map
one
transmembran
subunit
arteriviru
replicas
could
show
csa
treatment
interfer
eav
rna
synthesi
csaresist
mutat
render
replic
particular
rna
synthesi
less
sensit
csa
treatment
furthermor
show
resist
close
relat
cyp
inhibitor
alv
requir
addit
adapt
mutat
second
transmembran
subunit
arteriviru
replicas
essenti
polyprotein
process
ro
format
studi
implic
mechan
underli
sensit
arteriviru
replic
cyclophilin
inhibitor
treatment
moreov
suggest
role
cyclophilin
arteriviru
host
factor
specif
link
viral
rna
synthesi
possibl
interact
key
player
ro
format
membraneassoci
eav
rtc
isol
cell
vitro
rna
synthesi
assay
ivra
perform
essenti
describ
previous
van
hemert
et
al
short
approxim
eavinfect
cell
moi
harvest
h
pi
lyse
use
ballbear
homogen
isobiotek
clearanc
lysat
centrifug
min
x
g
obtain
post
nuclear
supernat
pn
standard
ivra
contain
pn
equival
x
infect
cell
concentr
csa
stock
final
concentr
rtc
dilut
buffer
control
perform
presenc
p
ctp
incorpor
newli
synthes
eav
rna
assay
incub
min
termin
addit
lidsletprotk
incub
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
plabel
reaction
product
isol
separ
denatur
agaros
gel
agaros
gel
dri
reaction
product
visual
phophorimag
use
aim
investig
mechanismofact
arteriviru
infect
inhibit
presenc
cyclophilin
inhibitor
end
wt
eav
strain
bucyru
moi
serial
passag
cell
presenc
increas
concentr
csa
three
independ
viru
lineag
gener
name
eav
exhibit
clearli
decreas
sensit
csa
fig
passag
three
lineag
replic
presenc
csa
data
shown
dose
approxim
higher
valu
observ
use
wteav
passag
absenc
csa
alter
drug
sensit
wteav
control
viru
csatreat
eav
lineag
becom
fivefold
less
sensit
compound
fig
tabl
note
addit
passag
passag
decreas
csa
sensit
next
confirm
reduc
csa
sensit
viru
infect
moi
cell
presenc
csa
dose
fulli
inhibit
wteav
replic
viru
product
measur
h
pi
confirm
infect
presenc
csa
inde
yield
detect
viru
progeni
fig
csa
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
concentr
titer
pfuml
eav
even
around
pfuml
eav
reach
infect
done
virus
three
csaresist
lineag
similar
result
obtain
cell
albeit
yield
three
lineag
equal
reduc
compar
cell
line
data
shown
csa
resistanceassoci
mutat
map
eav
order
identifi
csa
associ
mutat
consensu
genom
sequenc
three
csaresist
eav
sampl
determin
follow
rtpcr
amplif
tabl
fig
eav
consensu
sequenc
contain
three
mutat
map
region
result
three
amino
acid
substitut
mix
wt
sequenc
remark
mutat
also
encod
consensu
sequenc
eav
popul
accompani
mutat
untransl
region
one
specifi
mutat
helicas
domain
lineag
contain
mutat
lead
substitut
none
consensu
sequenc
contain
synonym
mutat
fix
passag
likewis
mutat
discov
consensu
sequenc
control
impli
mutat
identifi
virus
potenti
link
establish
reduc
sensit
csa
assess
import
identifi
mutat
csa
sensit
mutat
individu
revers
engin
eav
genom
use
fulllength
cdna
clone
recombin
mutant
virus
launch
csa
sensit
assay
cell
use
cpebas
assay
outlin
see
fig
interestingli
three
mutat
decreas
csa
sensit
eav
replic
valu
vs
wt
control
reav
wt
chang
sensit
observ
mutat
see
tabl
sfig
note
mutat
revert
back
wildtyp
residu
data
shown
like
explain
margin
decreas
csa
sensit
observ
assay
sfig
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
increas
csa
resist
observ
recombin
mutant
virus
singular
mutat
appear
smaller
approxim
increas
observ
virus
carri
multipl
substitut
therefor
also
engin
mutant
virus
genom
sequenc
ident
consensu
sequenc
three
csaresist
viru
lineag
lineag
contain
mix
q
wt
r
mutant
residu
variant
engin
test
compar
virus
carri
singular
mutat
mutant
reav
display
decreas
sensit
csa
approach
eav
lineag
fig
tabl
mutat
ad
csa
resist
diminish
slightli
compar
doubl
mutant
fig
tabl
vs
howev
upon
passag
resequenc
data
shown
doubl
mutant
appear
genet
instabl
may
also
explain
mix
sequenc
found
codon
lineag
consensu
sequenc
lineag
combin
three
mutat
utr
genom
improv
csa
resist
compar
reav
fig
lack
synergist
effect
indic
mutat
contribut
substanti
level
csa
resist
case
eav
combin
yield
decreas
csa
sensit
valu
compar
sfig
e
fig
see
tabl
suggest
mutat
contribut
csa
resist
overal
result
clearli
implic
variou
eav
mutat
reduc
csa
sensit
wherea
combin
mutat
increas
csa
resist
compar
singular
mutant
substitut
contribut
detect
csa
resist
mutant
reav
select
followup
experi
genet
stabl
upon
passag
data
shown
includ
singl
mutat
key
csa
resist
lineag
simplic
mutant
refer
reav
qya
point
forward
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
reav
qya
replic
presenc
csa
csa
resist
reav
qya
analyz
detail
infect
cell
presenc
absenc
csa
upon
highmoi
inocul
moi
replic
kinet
reav
wt
reav
qya
absenc
csa
similar
fig
solid
line
progeni
releas
reav
wt
reav
qya
infect
cell
h
pi
onward
reav
qya
titer
slightli
reduc
compar
reav
wt
presenc
csa
reav
wt
essenti
unabl
replic
reveal
obviou
differ
dmv
amount
size
ultrastructur
replic
reav
qya
presenc
csa
delay
compar
replic
untreat
cell
analyz
cell
infect
mutant
h
pi
fig
presenc
csa
dmv
observ
reav
wt
fig
morpholog
size
dmv
reav
qya
infect
cell
similar
structur
observ
upon
infect
untreat
cell
infect
reav
wt
reav
qya
fig
notabl
sever
compoundinduc
dilat
er
membran
observ
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
phenomenon
independ
eav
infect
also
observ
csatreat
infect
cell
compar
fig
taken
togeth
observ
strongli
suggest
csa
treatment
interfer
earli
stage
arteriviru
infect
ie
prior
ro
format
appar
adapt
mutat
compens
detriment
effect
csa
treatment
may
either
target
one
viral
player
directli
affect
host
factor
involv
arteriviru
replic
like
cyclophilin
see
purpos
cell
infect
reav
wt
reav
qya
viral
rna
synthesi
assay
metabol
label
h
uridin
h
pi
fig
b
cell
also
treat
dactinomycin
block
cellular
transcript
h
uridin
incorpor
viral
rna
quantifi
isol
intracellular
rna
liquid
scintil
count
fig
label
viral
rna
also
visual
agaros
gel
electrophoresi
fluorographi
fig
reveal
rna
synthesi
mutant
viru
approxim
wt
viru
activ
line
observ
delay
growth
kinet
reduc
titer
mutant
howev
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
presenc
csa
ad
h
prior
puls
label
reav
wt
rna
synthesi
complet
block
reav
qya
rna
synthesi
hardli
affect
evid
overal
quantif
hlabel
rna
rna
analysi
use
agaros
gel
electrophoresi
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
alisporivir
alv
de
wild
et
al
drug
explor
hostdirect
antivir
treatment
option
chronic
hcv
infect
naoumov
alv
lack
immunosuppress
properti
csa
retain
high
affin
cyclophilin
establish
alv
abl
block
also
replic
wteav
valu
effici
compar
observ
csa
tabl
explor
develop
alv
resist
eav
two
independ
passag
experi
cell
perform
eav
presenc
increas
alv
concentr
passag
passag
similar
approach
use
gener
csaresist
virus
fig
passag
cpebas
assay
reveal
compar
sensit
alv
reduc
eav
lineag
respect
fig
tabl
interestingli
sampl
eav
lineag
less
sensit
csa
well
fig
analysi
consensu
sequenc
reveal
popul
contain
multipl
mutat
tabl
includ
singular
mutat
region
structur
code
region
strikingli
virus
lineag
also
carri
two
substitut
two
mutat
previous
identifi
lineag
see
wherea
also
contain
mutat
present
strikingli
alvresist
lineag
contain
mutat
within
papainlik
proteas
domain
revers
engin
mutat
viral
genom
assay
alv
sensit
mutant
virus
singular
mutant
display
reduc
alv
sensit
mutant
also
less
sensit
csa
fig
tabl
subsequ
combin
mutat
synergist
effect
confirm
import
common
substitut
alv
resist
mutat
reduc
sensit
alv
data
shown
mutat
structur
proteincod
region
contribut
alv
resist
fig
tabl
final
corrobor
import
alv
resist
mutat
transfer
reav
qya
tripl
mutant
alreadi
carri
mutat
identifi
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
studi
csa
resist
see
anticip
tripl
mutant
margin
resist
alv
like
due
presenc
mutat
see
fig
addit
render
reav
qya
viru
nearli
insensit
alv
treatment
also
retain
reduc
csa
sensit
fig
result
clearli
confirm
highest
level
alv
resist
achiev
introduc
combin
adapt
mutat
eav
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
studi
demonstr
adapt
mutat
transmembran
replicas
subunit
reduc
sensit
eav
replic
csa
treatment
independ
experi
use
csa
analog
alv
point
direct
addit
implic
alv
sensit
resist
substitut
enabl
eav
toler
csa
alv
concentr
would
normal
block
viru
replic
fig
largest
increas
achiev
multipl
substitut
case
alv
combin
tabl
four
substitut
implic
csa
resist
residu
conserv
among
arterivirus
fig
interestingli
residu
also
part
potenti
cypa
bind
motif
gpxl
identifi
piotukh
et
al
constitut
potenti
interact
site
two
protein
howev
infect
mutat
quickli
revert
therefor
contribut
substitut
csa
resist
remain
unclear
three
mutat
present
predict
transmembran
domain
fig
therefor
may
directli
involv
interact
cyp
protein
experiment
data
avail
membran
topolog
upon
silico
model
mutat
appreci
alter
predict
conform
variou
transmembran
domain
data
shown
addit
em
analysi
dmv
format
upon
reav
qya
infect
reveal
ultrastructur
differ
either
absenc
presenc
csa
fig
clearli
detail
inform
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
analog
data
relev
adapt
mutat
eav
map
insid
first
last
four
predict
transmembran
domain
one
possibl
mechan
adapt
mutat
somehow
increas
stabil
rtc
complex
therebi
counteract
destabil
may
result
csa
penetr
lipid
membran
shown
csa
insert
destabil
membran
structur
prefer
sphingomyelinrich
membran
interestingli
despit
fact
csa
alv
cyclophilin
inhibitor
eav
resist
alv
requir
addit
mutat
proteas
domain
fig
suggest
compar
csa
alv
addit
target
relev
eav
replic
either
directli
indirectli
residu
posit
helix
domain
structur
distant
proteas
activ
site
surfac
involv
ubiquitin
bind
van
kasteren
et
al
featur
link
secondari
function
deubiquitinas
involv
arterivir
innat
immun
evas
unfortun
structur
domain
resolv
overal
fold
membran
topolog
subunit
eav
remain
unclear
studi
implic
viral
rna
synthesi
either
directli
indirectli
provid
evid
mutat
involv
reduc
sensit
csa
mutat
combin
substitut
contribut
alv
resist
futur
studi
aim
elucid
differ
mode
action
alv
csa
exact
role
arteriviru
sensit
resist
cyp
inhibitor
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
acknowledg
thank
ettor
ullo
jayron
habib
jessika
zevenhovendobb
died
oudshoorn
technic
assist
help
discuss
dr
vuagniaux
critic
read
manuscript
novarti
basel
switzerland
debiopharm
lausann
switzerland
provid
alisporivir
research
support
part
project
silver
grant
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
schreiber
sl
crabtre
gr
mechan
action
cyclosporin
immunol
today
zhang
w
chen
k
zhang
x
guo
c
chen
liu
x
integr
analysi
membran
remodel
porcin
reproduct
respiratori
syndrom
viru
replic
assembl
plo
one
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
well
plate
infect
reav
wt
control
black
line
reav
mutant
blue
reav
qya
red
reav
qya
green
presenc
alv
csa
base
quantif
rna
band
given
rel
abund
place
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
